George O. Waring, IV, M.D., discusses the latest technology improving eyesight for patients.
There have been developments in LASIK surgery improving outcomes for patients. George O. Waring, IV, M.D., founder and medical director of the Waring Vision Institute, discussed how new technology operates at a high-speed repetition rate with advanced features that result in highlight statistically significant improvements in contrast sensitivity after LASIK.
“We saw more patients gain best corrected vision by a factor of three times,” he said about the Technolas Teneo 317 Model 2.
Additionally, Waring highlighted the laser's unique capability of not requiring a nomogram, which minimizes the risk of human error during treatment. The laser has shown exceptional outcomes across a wide range of vision corrections, achieving an R-squared value of 0.98, indicating nearly perfect alignment between intended and actual results.
He also discussed the latest OmniVu data, noting promising long-term refractive stability over two years.
“This is truly a more physiological lens, that is to say, being capsule filling, we're not seeing subtle shifts in the effect of lens position,” Waring said. “When we stabilize the lens capsule and the capsular forces in a more physiologic way, we believe this answers one of the last unanswered opportunities in modern day refractive cataract surgery and that is the elusive effective lens position.”
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More